The Billion Dollar Blindspot

The Billion Dollar Blindspot

Home
Capital Briefing
Archive
About

Signal Not Noise

UCB Just Paid $2.2 Billion for an Autoimmune Platform. The Indication List Tells You More Than the Deal Price.
UCB’s acquisition of Candid Therapeutics is being framed as a next-generation immunology platform deal. But beneath the immune-reset narrative lies a…
 • Maryann Selfe
Two Approved Drugs. The Same Structural Problem. What the Menopause Market Is Actually Telling Investors.
The first non-hormonal menopause drug launched in 2023. Two and a half years later, the commercial case has not arrived. Bayer launched its competitor…
 • Maryann Selfe
Sun Pharma Agreed to Pay $11.75 Billion for Organon. The Portfolio Is Women's Health. The Thesis Is Not.
The largest overseas acquisition in Indian pharmaceutical history transferred the world's biggest dedicated women's health portfolio to a biosimilar…
 • Maryann Selfe
Gilead Just Paid $5 Billion for a European Biotech. The Indication Was Ovarian Cancer. That's Not a Coincidence.
The largest private European biotech exit in history followed a pattern that was visible before the announcement. Here's how to read it and what it…
 • Maryann Selfe
Organon Is Telling You Exactly What It Is and the Exit Math for Women's Health Has Changed
The sequence of decisions Organon made between October 2025 and March 2026 changes the exit landscape for every early-stage company building in…
 • Maryann Selfe
The Menopause Drug Market Just Split in Two and the Capital Opportunity Is Bigger Than Either Drug
Why inconsistent AI diagnoses aren’t a breakthrough, but a signal that both medicine and machine learning are built on incomplete data and what that…
 • Maryann Selfe
Signal Not Noise: Clarity’s FDA Win, Progyny x Amazon, and the Rise of Hormone Health Infrastructure
The Briefing for Backers of the Future of Health
 • Maryann Selfe
Signal Not Noise: Flo’s Data Reckoning, Evvy’s Expansion & Toxic Tampons Wake Up the Market
The Briefing for Backers of the Future of Health
 • Maryann Selfe
Signal Not Noise: Hologic’s Bet, Hormona’s Raise & Insurance-Backed Longevity for Women
Women’s health insights through an investor lens. Because headlines fade. Signals shape strategy.
 • Maryann Selfe
Signal Not Noise: What Mattered in Women’s Health Investing (May 11–May 17)
Women’s health insights through an investor lens. Because headlines fade. Signals shape strategy.
 • Maryann Selfe
Signal Not Noise: What Mattered in Women’s Health Investing (May 4–May 10)
Women’s health insights through an investor lens. Because headlines fade. Signals shape strategy.
 • Maryann Selfe
Signal Not Noise: What Mattered in Women’s Health Investing (Apr 27–May 3)
Women’s health insights through an investor lens. Because headlines fade. Signals shape strategy.
 • Maryann Selfe
© 2026 Maryann Selfe · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture